These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22407457)

  • 21. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
    Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
    J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
    Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
    Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
    Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of age on epidermal growth factor receptor mutation in lung cancer.
    Ueno T; Toyooka S; Suda K; Soh J; Yatabe Y; Miyoshi S; Matsuo K; Mitsudomi T
    Lung Cancer; 2012 Dec; 78(3):207-11. PubMed ID: 23036155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.
    Soung YH; Lee JW; Kim SY; Seo SH; Park WS; Nam SW; Song SY; Han JH; Park CK; Lee JY; Yoo NJ; Lee SH
    Virchows Arch; 2005 May; 446(5):483-8. PubMed ID: 15815931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No impact of passive smoke on the somatic profile of lung cancers in never-smokers.
    Couraud S; Debieuvre D; Moreau L; Dumont P; Margery J; Quoix E; Duvert B; Cellerin L; Baize N; Taviot B; Coudurier M; Cadranel J; Missy P; Morin F; Mornex JF; Zalcman G; Souquet PJ;
    Eur Respir J; 2015 May; 45(5):1415-25. PubMed ID: 25745045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specificities of lung adenocarcinoma in women who have never smoked.
    Mazières J; Rouquette I; Lepage B; Milia J; Brouchet L; Guibert N; Beau-Faller M; Validire P; Hofman P; Fouret P
    J Thorac Oncol; 2013 Jul; 8(7):923-9. PubMed ID: 23608817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
    Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
    Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
    La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
    Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.
    Zhang S; Xia B; Jiang H; Wang L; Xu R; Shi Y; Zhang J; Xu M; Cram DS; Ma S
    Oncotarget; 2016 Aug; 7(31):50477-50489. PubMed ID: 27409166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare mutations in non-small-cell lung cancer.
    D'Arcangelo M; D'Incecco A; Cappuzzo F
    Future Oncol; 2013 May; 9(5):699-711. PubMed ID: 23647298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.
    Shan L; Qiu T; Ling Y; Guo L; Zheng B; Wang B; Li W; Li L; Ying J
    PLoS One; 2015; 10(6):e0130447. PubMed ID: 26102513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of TP53 mutations on the prognosis of patients with early stage non-small cell lung cancer may depend on the intratumor heterogeneity of the mutations.
    Lee SY; Jeon HS; Hwangbo Y; Jeong JY; Park JY; Lee EJ; Jin G; Shin KM; Yoo SS; Lee J; Lee EB; Cha SI; Kim CH; Park JY
    Mol Carcinog; 2015 Feb; 54(2):93-101. PubMed ID: 24038464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of lung cancer in women: importance of hormonal and growth factors.
    Rouquette I; Lauwers-Cances V; Allera C; Brouchet L; Milia J; Nicaise Y; Laurent J; Delisle MB; Favre G; Didier A; Mazières J
    Lung Cancer; 2012 Jun; 76(3):280-5. PubMed ID: 22197614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distribution of molecular subtypes of advanced lung adenocarcinoma and clinical outcomes in a center of Argentina.
    Recondo G; Denninghoff V; Cuello MT; Lorente C; Greco M; De la Vega M; Avagnina A; Recondo G
    Medicina (B Aires); 2018; 78(6):385-394. PubMed ID: 30504104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma.
    Xu Y; Zhu C; Qian W; Zheng M
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):181-186. PubMed ID: 27738759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.
    Wright GM; Do H; Weiss J; Alam NZ; Rathi V; Walkiewicz M; John T; Russell PA; Dobrovic A
    Oncotarget; 2014 Apr; 5(8):2107-15. PubMed ID: 24742923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid detection of K-, N-, H-RAS, and BRAF hotspot mutations in thyroid cancer using the multiplex primer extension.
    Chang YS; Lin IL; Yeh KT; Chang JG
    Clin Biochem; 2013 Oct; 46(15):1572-7. PubMed ID: 23792105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.